Argatroban is a synthetic direct thrombin inhibitor and the chemical name is 1-[5- [(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, monohydrate. Argatroban has 4 asymmetric carbons. One of the asymmetric carbons has an R configuration (stereoisomer Type I) and an S configuration (stereoisomer Type II). Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65-35.
In the last several years, global market of Argatroban Industry decreased with the average production growth rate about -15%. In 2015, global capacity of Argatroban reduced to 34786 grams
from 65183 grams since 2011. It is predicted that the argatroban demand will continue to decrease with a average growth rate of -9% in the coming five years.
Japan is the still largest supplier of argatroban with the production market share of 35% and the consumption market share of 22% in 2015.
The price of argatroban is relatively expensive. The largest consumers are developed countries with high income. USA occupied a market share of 34%. The second place is Europe, following North America with the consumption market share of 22% in 2015.
China has few companies entering the market with production share of only 8%, and demand cannot be satisfied with supply. Large quantities of argatroban have to be imported.
Intially, compared with hirudin and heparin, the therapeutic dose has little effect on platelet, no antigen and strong antithrombotic effect. The sale value has reached 190 million USA dollars in 2008. But because of its narrow therapeutic area, uncertain factors on human?s bodies and fierce competition from other substitutes, it sales far less than other thrombin inhibitor. The value reduced to 101 million USA dollars in 2015.
According to this study, over the next five years the Argatroban market will register a -14.9% CAGR in terms of revenue, the global market size will reach USD 32 million by 2024, from USD 84 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Argatroban business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Argatroban market by product type, application, key manufacturers and key regions and countries.
This study considers the Argatroban value and volume generated from the sales of the following segments-
Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Argatroban Powder
Argatroban Injection
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Heparin-induced thrombocytopenia (HIT)
Percutaneous Coronary Intervention
Cerebral arterial thrombosis
This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Pfizer, Inc
SANDOZ
GlaxoSmithKline Plc
fresenius-kabi
Eagle Pharmaceuticals, Inc
Mitsubishi Tanabe Pharma
Teva Pharmaceutical Industries Ltd
WEST-WARD,INC
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Argatroban consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Argatroban market by identifying its various subsegments.
Focuses on the key global Argatroban manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Argatroban with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Argatroban submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
